• Voluntarily sign the informed consent form and comply with the study protocol requirements.

• Male or female, Age ≥18 years and ≤75 years at the time of signing the informed consent form.

• Diagnosed with stage II-IIIB (according to Version 8 of TNM staging) EGFR-sensitive mutation-positive non-small cell lung cancer (NSCLC) with feasibility or potential feasibility for radical surgery (radical lobectomy + systematic lymph node dissection), and assessed by the investigator as requiring neoadjuvant therapy.

• Adequate pulmonary function to tolerate surgery.

• Must have at least one measurable lesion per RECIST v1.1 criteria.

• Eastern Cooperative Oncology Group (ECOG) performance status score of ≤1.

• No severe cardiac dysfunction, with left ventricular ejection fraction (LVEF) ≥50%.

• Organ function levels must meet the following criteria:

∙ Bone marrow function: Absolute neutrophil count (ANC) ≥1.5×10⁹/L, platelet count ≥100×10⁹/L, hemoglobin ≥90 g/L;

‣ Hepatic function: Total bilirubin (TBIL) ≤1.5×ULN, AST and ALT ≤2.5×ULN;

‣ Renal function: Serum creatinine (Cr) ≤1.5×ULN or creatinine clearance (Ccr) ≥50 mL/min (calculated by Cockcroft-Gault formula);

‣ Albumin ≥30 g/L.

• Coagulation function: International normalized ratio (INR) ≤1.5 and activated partial thromboplastin time (APTT) ≤1.5×ULN.

⁃ Urine protein: ≤2+ on dipstick or ≤1000 mg/24h.

⁃ Contraception: Females of childbearing potential or males with partners of childbearing potential must use highly effective contraception from 7 days before the first dose until 6 months after the last dose. Females of childbearing potential must have a negative serum pregnancy test within 7 days prior to the first dose.